After a week of unremitting and unprecedented pressure from FDA, CMS, Congress, medical societies and the public, it isn't clear whether KV Pharmaceutical Co. will be able to market its pregnancy drug Makena at a price that makes the company financially viable.

The company announced last Friday it had slashed the list price by 54% to $690 per dose, and implemented new cost caps and patient assistance measures, but the moves did little to quell the anger.